Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Neurometabolic therapy in the recovery period of ischemic stroke: impact on quality of life and cognitive functions

https://doi.org/10.14412/2074-2711-2016-2-87-93

Full Text:

Abstract

Some recovery of impaired neurological functions (a stroke recovery period) is almost always observed within the first 6–24 months after ischemic stroke (IS). The paper discusses the mechanisms responsible for this process (neurogenesis, neuroplasticity, and readaptation) and possible approaches to the drug support of cerebral reparative processes. It presents data on the rate and etiology of poststroke cognitive impairments (CI) that are one of the important factors that negatively influence the outcome of rehabilitation measures. The results obtained from a recent study of the efficacy of the neurometabolic agent citicoline in the recovery period of IS are given. The use of citicoline is shown to cause a significant regression of CI and to improve quality of life in patients who have sustained IS for the first time. 

About the Authors

V. V. Zakharov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Nervous System Diseases and Neurosurgery

11, Rossolimo St., Moscow 119021 



N. V. Vakhnina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Nervous System Diseases and Neurosurgery

11, Rossolimo St., Moscow 119021 



D. O. Gromova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Nervous System Diseases and Neurosurgery

11, Rossolimo St., Moscow 119021 



References

1. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]

2. Стаховская ЛВ, Котова СВ. Инсульт. Руководство для врачей. Москва: МИА; 2014. 400 с. [Stakhovskaya LV, Kotova SV. Insul't. Rukovodstvo dlya vrachei [Stroke. A guide for physicians]. Moscow: MIA; 2014. 400 p.]

3. Jacquin A, Binquet C, Rouaud O, et al. Poststroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40(4):1029-38. doi: 10.3233/JAD-131580.

4. Rasquin SM, Verhey FR, van Oostenbrugge RJ, et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1562-7.

5. Ihle-Hansen H, Thommessen B, Wyller TB, et al. Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord. 2011;32(6):401-7. doi: 10.1159/000335361. Epub 2012 Feb 3.

6. Srikanth VK, Anderson JF, Donnan GA, et al. Progressive dementia after first-ever stroke: a community-based follow-up study. Neurology. 2004 Sep 14;63(5):785-92.

7. Srikanth VK, Thrift AG, Saling MM, et al. Increased risk of cognitive impairment 3 months after mild to moderate first-ever stroke: a Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke. 2003 May;34(5):1136-43. Epub 2003 Apr 17.

8. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord. 2006;21(5-6):275-83. Epub 2006 Feb 10.

9. Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke. 2004 Jun;35(6):1264-8. Epub 2004 Apr 29.

10. Lisabeth LD, Sanchez BN, Baek J, et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke. 2014 Apr;45(4):1096-101. doi: 10.1161/STROKEAHA.113.003912. Epub 2014 Mar 13.

11. Tham W, Auchus AP, Thong M, et al. Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci. 2002 Nov 15;203-204:49-52.

12. Das S, Paul N, Hazra A, et al. Cognitive dysfunction in stroke survivors: a communitybased prospective study from Kolkata, India. J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1233- 42. doi: 10.1016/j.jstrokecerebrovasdis.2012.03.008. Epub 2012 Jun 19.

13. Вербицкая СВ, Парфенов ВА. Клинический опыт применения мемантина при постинсультной деменции. Неврологический журнал. 2008;13(4):45-7. [Verbitskaya SV, Parfenov VA. Clinical experience of the use of memantine in post-stroke dementia. Nevrologicheskii zhurnal. 2008;13(4):45-7. (In Russ.)].

14. Парфенов ВА, Вахнина НВ, Никитина ЛЮ. Когнитивные нарушения после инсульта и их лечение мемантином. Клиническая геронтология. 2005;11(8):49-52. [Parfenov VA, Vakhnina NV, Nikitina LYu. Cognitive impairment after stroke and their treatment with memantine. Klinicheskaya gerontologiya. 2005;11(8):49-52. (In Russ.)].

15. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline trial on acute stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicenter, placebo-controlled study (ICTUS trial). Lancet. 2012 Jul 28;380(9839):349-57. doi: 10.1016/S0140- 6736(12)60813-7. Epub 2012 Jun 11.

16. The management of stroke rehabilitation group. VA/DoD clinical practice guideline for the management of stroke rehabilitation in the primary care setting. West Virginia medical institute incorporation; 2003. 56 p.

17. Дамулин ИВ. Основные механизмы нейропластичности и их клиническое значение. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(4):4-8. [Damulin IV. The basic mechanisms of neuroplasticity and their clinical significance. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(4):4-8. (In Russ.)].

18. Гусев ЕИ, Скворцова ВИ. Ишемия го- ловного мозга. Москва: Медицина; 2001. 325 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 325 p.]

19. Liu J, Solway K, Messing RO, Sharp FR. Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci. 1998 Oct 1;18(19):7768-78.

20. Sharp FR, Liu J, Bernabeu R. Neurogenesis following brain ischemia. Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):23-30.

21. Sun X, Zhang QW, Xu M, et al. New striatal neurons form projections to substantia nigra in adult rat brain after stroke. Neurobiol Dis. 2012 Jan;45(1):601-9. doi: 10.1016/j.nbd.2011.09.018. Epub 2011 Oct 8.

22. Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997 Apr 3;386(6624):493-5.

23. Rizzi S, Bianchi P, Guidi S, et al. Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. Brain Res. 2011 Sep 30;1415:23-33. doi: 10.1016/j.brainres.2011.08.007. Epub 2011 Aug 9.

24. Ярыгин КН, Ярыгин ВН. Нейрогенез в центральной нервной системе и перспективы регенеративной неврологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(1):4-13. [Yarygin KN, Yarygin VN. Neurogenesis in the Central nervous system and prospects of regenerative neurology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(1):4-13. (In Russ.)].

25. Tillerson JL, Miller GW. Forced limb-use and recovery following brain injury. Neuroscientist. 2002 Dec;8(6):574-85.

26. Niеto-Sampedro M, Nieto-Dias M. Neural plasticity: changes with age. J Neural Transm (Vienna). 2005 Jan;112(1):3-27. Epub 2004 Jun 18.

27. World Health Organization. Neuroplasticity and repair in the central nervous system. Implications for Health Care. Geneva: WHO; 1983. P. 56.

28. Gage FH. Structural plasticity of the adult brain. Dialogues Clin Neurosci. 2004 Jun;6(2):135-41.

29. Butefisch CM. Plasticity in the human cerebral cortex: lessons from the normal brain and from stroke. Neuroscientist. 2004 Apr;10(2): 163-73.

30. Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001 Jun;124(Pt 6):1171-81.

31. Васильев АС, Бабенков НВ, Носенко ЕМ и др. Реабилитация и ведение больных с полушарным инсультом в свете новой концепции патогенеза постинсультного двигательного дефицита. Клинический вестник. 2001;(2):34-7. [Vasil'ev AS, Babenkov NV, Nosenko EM, et al. Rehabilitation and management of patients with hemispheric stroke in the light of the new concept of the pathogenesis of post-stroke motor deficit. Klinicheskii vestnik. 2001;(2):34-7. (In Russ.)].

32. Дамулин ИВ, Кононенко ЕВ. Статолокомоторные нарушения у больных с полушарным инсультом. Клиническая геронтология. 2007;13(8):42-9. [Damulin IV, Kononenko EV. Statolocomotor disorders in patients with hemispheric stroke. Klinicheskaya gerontologiya. 2007;13(8):42-9. (In Russ.)].

33. Кадыков АС, Шахпаронова НВ. Реабилитация после инсульта. Русский медицинский журнал. 2003;11(25):1390-4. [Kadykov AS, Shakhparonova NV. Rehabilitation after a stroke. Russkii meditsinskii zhurnal. 2003;11(25):1390-4. (In Russ.)].

34. Gutierrez-Fern?ndez M, Rodriguez-Frutos B, Fuentes B, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 2012 Feb;60(3):310-7. doi: 10.1016/j.neuint. 2011.12.015. Epub 2011 Dec 30.

35. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011 Mar 14;52 Suppl 2:S1-S62.

36. Arenth PM, Russell KC, Ricker JH, Zafonte RD. CDP-choline as a biological supplement during neurorecovery: a focused review. PM R. 2011 Jun;3(6 Suppl 1):S123-31. doi: 10.1016/j.pmrj.2011.03.012.

37. Akasaki K, Uchida K, Fujikawa R, et al. Neuroprotective effects of citidine-5- diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci. 2011;116(2):232-7. Epub 2011 May 25.

38. Secades J, Frontera G. CDP-choline: Pharmacological and clinical review. Methods Find Exp Clin Pharvacol. 1995 Oct;17 Suppl B:1-54.

39. Hurtado O, Lizasoain I, Moro MА. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011 Jan;42 (1 Suppl):S33-5. doi: 10.1161/STROKEАHA. 110.597435. Epub 2010 Dec 16.

40. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995;56(9):637-60.

41. Alvarez-Sabin J, Santamarina E, Maisterra O, et al. Long-term treatment with citicoline prevents cognitive decline and predicts quality of life after first ischemic stroke. Int J Mol Sci. 2016 Mar 16;17(3). pii: E390. doi: 10.3390/ijms17030390..

42. Agnoli A, Bruno G, Fioravanti M. Therapeutic approach to senile memory impairment: a double-blind clinical trial with CDP choline. In: Wurtman RJ, Corkin S, Growden JH, editors. Alzheimer’s Disease: Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Boston, MA: Birkhauser;1989. P. 649-54.

43. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000269.

44. Abad-Santos F, Novalbos-Reina J, Gallego-Sandin S, Garcia AG. Tratamiento del deterioro cognitivo lieve: utilidad de la citicolina. Rev Neurol. 2002 Oct 1-15;35(7):675-82.

45. Caamargo J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994 Apr;16(3):211-8.

46. Alvarez XA, Mouzo R, Pichel V, et al. Doubleblind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44.

47. Franco-Maside A, Caamano J, Gomez MJ, Cacabelos R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994 Oct;16(8):597- 607.

48. Fernandez-Novoa L, Alvarez XA, Franco-Maside A, et al. CDP-choline-induced blood histamine changes in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994 May;16(4):279-84.

49. Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 192 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 192 p.]


For citation:


Zakharov V.V., Vakhnina N.V., Gromova D.O. Neurometabolic therapy in the recovery period of ischemic stroke: impact on quality of life and cognitive functions. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):87-93. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-87-93

Views: 361


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)